Evaxion’s AI-Powered Cancer Vaccine Hits 86% Target Precision in Phase 2 Trial — Evaxion A/S

Event summary

Evaxion’s AI-Immunology™ platform achieved 86% vaccine target precision in a phase 2 trial for its personalized cancer vaccine EVX-01.
The trial, conducted in advanced melanoma patients, showed durable immune responses and a 75% objective response rate.
Data will be presented at the AACR Annual Meeting on April 22, 2026.
EVX-01 is designed to work in combination with Merck’s KEYTRUDA® (pembrolizumab).

The big picture

Evaxion’s strong phase 2 results underscore the potential of AI in precision oncology, particularly in enhancing vaccine efficacy. The partnership with Merck’s KEYTRUDA® adds credibility, positioning Evaxion as a key player in the next wave of immuno-oncology treatments. Success here could accelerate adoption of AI-driven drug discovery across the biotech sector.

What we're watching

Clinical Validation: Whether the 86% target precision can be replicated in larger, more diverse patient populations.
Regulatory Pathway: The pace at which Evaxion advances EVX-01 toward regulatory approval, particularly in combination with KEYTRUDA®.
Competitive Positioning: How Evaxion’s AI-driven approach differentiates it from traditional cancer vaccine developers.